The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer

Thorax

Volumn 54, Issue 2, 1999, Pages 169-179

  Cox, G ^a   Steward, W P ^a   O'Byrne, K J ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; MATRIX METALLOPROTEINASE; PLASMIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; APOPTOSIS; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0033052090     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.2.169     Document Type: Review

References (208)

1. 1 Yurchenco PD, Cheng YS, Colognato H. Laminin forms an independent network in basement membranes. J Cell Biol 1992;117:1119-33.
2. 2 Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
3. 3 Barsky SH, Siegal GP, Jannotta F, et al. Loss of basement membrane components by invasive tumours but not by their benign counterparts. Lab Invest 1983;49:140-7.
4. 4 Liotta LA, Rao N, Barsky SH. Tumour invasion and the extracellular matrix. Lab Invest 1983;49:636-49.
5. 5 Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062-72.
6. 6 Besser D, Verde P, Nagamine Y, et al. Signal transduction and the u-PA/uPAR system. Fibrinolysis 1996;10:215-37.
7. 7 Dano K, Andreasen PA, Grondahl-Hansen K, et al. Plasminogen activators tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
8. 8 Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986;261:3486-9.
9. 9 Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumour cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 1991;266: 5147-52.
10. 10 Goretzki L, Schmitt M, Mann K, et al. Effective activation of the pro-enzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 1992;297:112-8.
11. 11 Yoshida E, Ohmura S, Sugiki M, et al. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer 1995;63:683-5.
12. 12 Stoppelli MP, Tacchetti C, Cubellis MV, et al. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986;45:675-84.
13. 13 Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumour invasion. Physiol Rev 1993;73:161-95.
14. 14 Plow EF, Miles LA. Plasminogen receptors in the mediation of pericellular proteolysis. Cell Differentiation Develop 1990; 32:293-8.
15. 15 Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function and regulation. J Biol Chem 1994;269:15957-60.
16. 16 Cubellis MV, Andreasen PA, Ragno PA, et al. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci 1989;989;86:4828-32.
17. 17 Ellis V, Wun T-C, Behrendt N, et al. Inhibition of receptor-bound urokinase by plasminogen activator inhibitor. J Biol Chem 1990;265:9904-8.
18. 18 Laug WE, Cao XR, Yu YB, et al. Inhibition of invasion of HT-1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993;53:6051-7.
19. 19 Jensen PH, Christensen EI, Ebbesen P, et al. Lyposomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell Regul 1990;1: 1043-56.
20. 2-macroglobulin receptor mediates cellular degradation of urokinase receptor bound complexes. J Biol Chem 1992;267:14543-6.
21. 21 Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4:197-250.
22. 22 Van Wart H, Birkedal-Hansen H. The cysteine switch: a principal regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990;87:5578-82.
23. 23 He C, Wilhelm SM, Pentland AP, et al. Tissue co-operation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci 1989;86:2632-6.
24. 24 Kleiner DJ, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 1993;5:891-7.
25. 25 Brown PD, Kleiner DE, Unsworth EJ, et al. Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex. Kidney Int 1993;43:163-70.
26. 26 Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
27. 27 Stricklin GP, Welgus HG. Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization. J Biol Chem 1983;258:12252-8.
28. 28 Herron GS, Banda MJ, Clark EJ, et al. Secretion of metalloproteinases by stimulated capillary endothelial cells. J Biol Chem 1986;261:2814-8.
29. 29 Gavrilovic J, Hembry RM, Reynolds JJ, et al. Tissue inhibitor of metalloproteinases (TIMP) regulates extracellular type 1 collagen degradation by chondrocytes and endothelial cells. J Cell Sci 1987;87:357-62.
30. 30 DeClerck YA. Purification and characterisation of a collagenase inhibitor produced by bovine vascular smooth muscle cells. Arch Biochem Biophys 1988;265:28-37.
31. 31 Leco KJ, Khokha R, Pavloff N, et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;269:9352-60.
32. 32 Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinase (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995;270:14313-8.
33. 33 Goldberg GI, Strongin A, Collie IE, et al. Interaction of 92-kDa type IV collagenases with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme by stromelysin. J Biol Chem 1992;267:4583-91.
34. 34 Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72 and 92 kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem 1991;266:13070-5.
35. 35 Leco KJ, Apte SS, Taniguchi GT, et al. Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997;401: 213-7.
36. 36 Bigg HF, Shi YE, Liu YE, et al. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem 1997;272:15496-500.
37. 37 Khokha P, Waterhouse P, Yagel S, et al. Antisense RNA-induced reduction in metalloproteinase inhibitor causes mouse 3T3 cells to become tumorigenic. Science 1989;243:947-50.
38. 38 Mann JS, Kindy MS, Edwards DR, et al. Hormonal regulation of matrix metalloproteinase inhibitors in rat granulosa cells and ovaries. Endocrinology 1991;128:1825-32.
39. 39 Pyke C, Ralfkaier E, Tryggvason K, et al. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 1993;142:359-65.
40. 40 Heppner KJ, Matrisian LM, Jensen RA, et al. Expression of most matrix metalloproteinase family members in breast cancer represents a tumour induced host response. Am J Pathol 1996;149:273-82.
41. 41 Autio Harmainen H, Kartunnen T, Hurskainen T, et al. Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumours. Lab Invest 1993;69:312-21.
42. 42 Odekon LE, Sato Y, Rifkin DB. Urokinase-type plasminogen activator mediates basic growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992;150:258-63.
43. 43 Binder BR. Influence of urokinase on cell proliferation and invasion. Blood Coagul Fibrinolysis 1990;1:717-20.
44. 44 Pepper MS, Matsumoto K, Nakamura T, et al. Upregulation of urokinase receptor expression on migratory endothelial cells. J Cell Biol 1993;122:673-84.
45. 45 Liu G, Shuma MA, Cohen RL. Coexpression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995;60:501-6.
46. 46 Kobayashi H, Gotoh J, Fujie M, et al. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer 1994;57: 727-33.
47. 47 Kjoller L, Kanse S, Kirkegaard T, et al. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997;232:420-9.
48. 48 Schlechte W, Brattain M, Boyd D. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display. Cancer Comm 1990;2:173-9.
49. 49 Meissauer A, Kramer MD, Hofmann M, et al. Urokinase-type and tissue-type plasminogen activators are essential for the in vitro invasion of human melanoma cells. Exp Cell Res 1991;192:453-9.
50. 50 Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994;54:3066-71.
51. 51 Glass WF, Radnik RA, Garoni JA, et al. Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangial cells. J Clin Invest 1988;82:1992-2000.
52. 52 Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancel 1997;72:1-22.
53. 53 Gyetko MR, Todd RF, Wilkinson CC, et al. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994;93:1380-7.
54. 54 Wang N, Planus E, Pouchelet M, et al. Urokinase receptor mediates mechanical force across cell surface. Am J Physiol 1995;C1062-6.
55. 55 Dumler I, Petri T, Schleuning W-D. Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett 1993;322:37-40.
56. 56 Dumler I, Petri T, Schleuning W-D. Induction of the c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett 1994;343:103-6.
57. 57 Clark EA, Brugge JS. Integrins and signal transduction pathways. Science 1995;268:233-9.
58. 58 Pepper MS, Ferrara N, Orci L, et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181: 902-6.
59. 59 Sappino AP, Busso N, Belin D, et al. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987;47:4043-6.
60. 60 Ornstein DL, Zacharski LR, Memoli VA, et al. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer 1991;68:1061-7.
61. 2-macroglobulin receptor in human breast carcinomas. Int J Cancer 1996;66:441-52.
62. 62 Buo L, Lyberg T, Jorgensen L, Johansen HT, et al. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. Acta Pathol Microbiol Immunol Scand 1993;101:235-41.
63. 63 Bolon I, Gouyer V, Devouassoux M, et al. Expression of c-ets-1, collagenase-1 and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 1995;147: 1298-310.
64. 64 Pyke C, Ralfkiaer E, Ronne E, et al. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994;24:131-8.
65. 65 Reilly D, Christensen L, Duch M, et al. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992;50:208-14.
66. 66 Garbisa S, Pozatti R, Muschel R, et al. Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not with c-Ha-ras plus Ad2-E1a. Cancer Res 1987;47:1523-8.
67. 67 Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996;32A:2528-33.
68. 68 Kawamata H, Kameyama S, Kawai K, et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 1995;63:568-75.
69. 69 Valente P, Fassina G, Melchiori A, et al. TIMP-2 overexpression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246-53.
70. 70 Schultz RM, Silberman S, Persky B, et al. Inhibition of recombinant tissue inhibitor of metalloproteinases of human amniotic invasion and lung colonisation by murine B16-F10 melanoma cells. Cancer Res 1988;48:5539-45.
71. 71 Montgomery AM, Mueller BM, Reisfield RA, et al. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994;54:5467-73.
72. 72 Khokha R, Denhardt DT. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 1989;9:391-405.
73. 73 Muller D, Breathnach R, Engelmann A, et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 1991;48:550-61.
74. 74 Kawano N, Osawa H, Ito T, et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an histochemical study. Hum Pathol 1997;28:613-22.
75. 75 Urbanski SJ, Edwards DR, Maitland A, et al. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992;66:1188-94.
76. 76 Brown PD, Bloxidge RE, Stuart NSA, et al. Association between expression of 72-kilodalton gelatinase and tumour spread in non-small cell lung cancer. J Natl Cancer Inst 1993;85:574-8.
77. 77 Bolon I, Devouassoux M, Robert C, et al. Expression of urokinase-type plasminogen activator, stromelysin-1, stromelysin-3 and matrilysin genes in lung carcinomas. Am J Pathol 1997;150:1619-29.
78. 78 Tokaraku M, Sato H, Murakami S, et al. Activation of the precursors of gelatinase A/72kDa type IV collagenase/ MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinases (MT-MMP) and with lymph node metastasis. Int J Cancer 1995;64:355-9.
79. 79 Basset P, Bellocq JP, Wolf C, etl al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704.
80. 80 Sato H, Kida Y, Mai M, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992;7:77-83.
81. 81 Boag AH, Young ID. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in-situ hybridization. Am J Pathol 1994;144:585-91.
82. 82 Nomura H, Sato H, Seiki M, et al. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995;55:3263-6.
83. 83 Tomita T, Iwata K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 1996;39:1255-64.
84. 84 Polette M, Gilbert N, Stas I, et al. Gelatinase A expression and localization in human breast cancers. An ISH study and immunohistochemical detection using confocal microscopy. Virchows Arch 1994;426:20-35.
85. 85 Davies B, Miles DW, Happerfield MLC, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67:1126-31.
86. 86 Iwata H, Kobayashi S, Iwase H, et al. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jap J Cancer Res 1996;87:602-11.
87. 87 Collier IE, Wilhelm SM, Eisen AZ, et al. H-ras oncogene-transformed bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement collagen. J Biol Chem 1988;263:6570-87.
88. 88 Monteagudo C, Merino MJ, San-Juan J, et al. Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 1990;136: 585-92.
89. 89 Nawrocki B, Polette M, Marchand V, et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantitative and morphological analyses. Int J Cancer 1997;72:556-64.
90. 90 Polette M, Nawrocki B, Gilles C, et al. MT-MMP expression and localization in human lung and breast cancers. Virchows Arch 1996;428:29-35.
91. 91 Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;85:683-93.
92. 92 Bafetti LM, Young TN, Itoh Y, et al. Intact vitronectin induces: matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem 1998;273:143-9.
93. 93 Klominek J, Robert KH, Sundquist KG. Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance. Cancer Res 1993;53:4376-82.
94. 94 Taraboletti G, Roberts DD, Liotta LA. Thrombospondin-induced tumour cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J Cell Biol 1987;105:2409-15.
95. 95 Baker SE, Hopkinson SB, Fitchmun M. Laminin-5 and hemidesmosomes: role of the alpha 3 subunit in hemidesmosome stability and assembly. J Cell Sci 1996; 109:2509-20.
96. 96 Gianelli G, Falk-Marzillier J, Schiraldi O, et al. Induction of cell migration by matrix metallopratease-2 cleavage of laminin-5. Science 1997;277:225-8.
97. 97 Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of metalloproteinase 9 (92-kDa gelatinase/ collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Nat Acad Sci 1994;91:4293-7.
98. 98 Hua J, Muschel RJ. Inhibition of matrixmetalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56:5279-84.
99. 90 Cannette-Soler R, Litzky L, Lubensky I, et al. Localization of the 92-kD gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in-situ hybridization. Am J Pathol 1994;144:518-27.
100. 100 Buisson AC, Gilles C, Polette M, et al. Wound repair-induced expression of stromelysins is associated with the acquisition of a mesenchymal phenotype in human respiratory epithelial cells. Lab Invest 1996;74:658-69.
101. 101 Bolon I, Brambilla E, Vandenbunder B, et al. Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions. Lab Invest 1996;75:1-13.
102. 102 Newell KJ, Witty JP, Rodgers WH, et al. Expression and localization of matrix-degrading metalloproteinase during colorectal tumorigenesis. Mol Carcinog 1994;10:199-206.
103. 103 Powell WC, Knox JD, Navre M, et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993;53:417-22.
104. 104 Wilson CL, Heppner KJ, Labosky PA, et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Nat Acad Sci USA 1997;94:1402-7.
105. 105 Testa JE. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2. Cancer Res 1992;52:5597-603.
106. 106 Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996;56:1654-9.
107. 107 Hewitt RE, Leach IH, Powe DG, et al. Distribution of collagenases and tissue inhibitors of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991;49:666-72.
108. 108 De Clerk YA, Perez N, Schimar H, et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-8.
109. 109 Powe DG, Brough JI, Carter GI, et al. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer 1997;75:1678-83.
110. 110 Anand-Apte B, Pepper MS, Voest E, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Investig Ophthalmol Vis Sci 1997;38:817-23.
111. 111 Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990;110:767-75.
112. 112 Naldini L, Tamagnone L, Vigna E, et al. Extracellular proteolytic cleavage by urokinase is required for the activation of hepatocyte growth factor/scatter factor. EMBO J 1992;11:4825-33.
113. 113 Sato Y, Tsubo R, Lyons R, et al. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self regulating system. J Biol Chem 1990;111:757-63.
114. 114 Witty JP, McDonnell S, Newell K, et al. Modulation of matrilysin levels in colon carcinoma cell lines affect tumorigenicity in vivo. Cancer Res 1994;54:4805-12.
115. 115 Morris VL, Koop S, MacDonald IC, et al. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis 1994;12:357-67.
116. 116 Koop S, Khokha R, Schmidt EC, et al. Overexpression of metalloproteinase inhibitor in B16 F10 cells does not affect extravasation but reduces tumour growth. Cancer Res 1994;54:4791-7.
117. 117 Khokha R, Zimmer MJ, Wilson SM, et al. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis 1992;32:365-70.
118. 118 Imren S, Kohn DB, Schimar H, et al. Over expression of tissue inhibitor of metalloproteinases-2 by retroviral mediated gene transfer in vivo inhibits tumour growth and invasion. Cancer Res 1996;56:2891-5.
119. 119 Wang M, Liu YE, Greene J, et al. Inhibition of tumour growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997;14:2767-74.
120. 120 Stetler-Stevenson WG, Krutsch FIC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). J Biol Chem 1989;264:17374-8.
121. 121 Hayakawa T, Yamashita K, Ohuchi E, et al. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994;107:2373-9.
122. 122 Bertaux B, Hornebeck W, Eisen AZ, et al. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991;97:679-85.
123. 123 Docherty AJP, Lyons A, Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985;318: 66-9.
124. 124 Clark IM, Powell LK, Cawston TE. Tissue inhibitor of metalloproteinases (TIMP-1) stimulates secretion of collagenase from human skin fibroblasts. Biochem Biophys Res Comm 1994;203:874-80.
125. 125 Boudreau N, Sympson CJ, Werb Z, et al. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995;267:891-5.
126. 126 Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17: 6330-8.
127. 127 Ahonen M, Baker AH, Kahari V-M. Adenovirus-mediated gene delivery of tissue-inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998;58:2310-5.
128. 128 Baker AH, Zaltsman AB, George SJ, et al. Divergent effects of tissue inhibitors of metalloproteinase-1, -2 or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation and death in vitro: TIMP-3 promotes apoptosis. J Clin Invest 1998;101:1478-87.
129. 129 Bain J, Wang Y, Smith MR, et al. Suppression of in vivo tumour growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 1996;17:1805-11.
130. 130 Smith MR, Kung H, Durum SK, et al. TIMP-3 induces cell death by stabilizing TNF-α receptors on the surface of human colon carcinoma cells. Cytokine 1997;9:770-80.
131. 131 Ray CA, Black RA, Kronheim SR, et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 1992;69:597-604.
132. 132 Billstrom A, Lecander I, Astedt B, et al. Recombinant PAI-2 inhibition of uPA-producing tumours in SCID-mice. Proceeding XIIth International Congress on Fibrinolysis 1994;8(Suppl 1):56.
133. 133 Gleeson N, Gonsalves R, Bonnar J. The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. Gynecol Oncol 1992;47:58-61.
134. 134 Weidner N, Folkman J, Pozza F, et al. Tumour angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-7.
135. 135 Giatromanolaki A, Koukourakis M, O'Byrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996;179:80-8.
136. 136 Fontanini G, Vignati S, Bigini D, et al. Neoangiogenesis: a putative marker of malignancy in non-small-cell lung cancer (NSCLC) development. Int J Cancer 1996;67:615-9.
137. 137 Takanami I, Tanaka F, Hashizume T, et al. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res 1997;17:2811-4.
138. 138 Mattern J, Koomagi R, Volm M. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Anticancer Res 1997;17: 2249-52.
139. 139 Koukourakis MI, Giatromanolaki A, O'Byrne KJ, et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small cell lung cancer. Br J Cancer 1997;75:477-81.
140. 140 Koukourakis MI, Giatromanolaki A, O'Byrne KJ, et al. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small cell lung cancer. Int J Cancer 1997;74: 565-70.
141. 141 Hildenbrand R, Dilger I, Horlin A, et al. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995;72: 818-23.
142. 142 Johnson MD, Kim H-RC, Chesler L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinases. J Cell Physiol 1994;160:194-202.
143. 143 Itoh T, Ikeda T, Gomi H, et al. Unaltered secretion of B-amyloid precursor in gelatinase A (matrix metalloproteinase-2)-deficient mice. J Biol Chem 1997;272: 22389-92.
144. 144 Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumour progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-51.
145. 145 Kato Y, Nakayama Y, Umeda M, et al. Induction of 103 kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 1992;267:11424-30.
146. 146 Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-46.
147. 147 Takigawa M, Nishida Y, Suzuki F, et al. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). Biochem Biophys Res Commun 1990;171:1264-71.
148. 148 Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue-inhibitor of metalloproteinases-2 inhibits bFGF induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-8.
149. 149 Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumour growth in syngenic mice. Cancer Res 1996;56:2428-33.
150. 150 Vlodavsky I, Fuks Z, Ashai-Michaeli R, et al. Extracellular matrix-resident basic fibroblast growth factor: implications for control of angiogenesis. J Cell Biochem 1991;47:167-76.
151. 151 Pepper MS, Belin D, Montesano R, et al. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990;111:743-55.
152. 152 Levi E, Fridman R, Miao H-Q, et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996;93: 7069-74.
153. 153 Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555-7.
154. 154 Crowe P, Walter BN, Mohler KM, et al. A metalloproteinase inhibitor blocks shedding of the 80 kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995;181:1205-10.
155. 155 Unemori EN, Ferrara N, Baurer EA, et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1991;153:557-62.
156. 156 Fisher C, Gilbertson-Beadling S, Powers EA, et al. Interstitial collagenase is required for angiogenesisin vitro. Dev Biol 1994;162:499-510.
157. 157 Lamoreaux WJ, Fitzgerald MEC, Reiner A, et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvascular Res 1998;55:29-42
158. 158 Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272: 28823-5.
159. 159 Dong Z, Kumar R, Fidler IJ. Generation of the angiogenesis inhibitor, angiostatin, by Lewis lung carcinoma is mediated by macrophage elastase. Proc Am Assoc Cancer Res 1996;37:403a.
160. 160 O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor in angiogenesis and tumour growth. Cell 1997;88:277-85.
161. 161 Ji WR, Barrientos LG, Llinas M, et al. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun 1998;247:414-9.
162. 162 O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79: 315-28.
163. 163 Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenic inhibitor TNP-470 (AGM-1470). Br J Cancer 1994;69:212-6.
164. 164 Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995;1:149-53.
165. 165 Clifton F, Mountain MD. Revisions in the international system for staging lung cancer. Chest 1997;111:1711-7.
166. 166 Duffy MJ. Plasminogen activators and cancer. Blood Coagul Fibrinolysis 1990;1:681-7.
167. 167 Duffy MJ, O'Grady P, Devancy D, et al. Urokinase-plasminogen activator, a marker for aggressive breast cancers. Preliminary report. Cancer 1988;62:531-3.
168. 168 Hasui Y, Marutsuka K, Suzumiya J, et al. The content of urokinase-type plasminogen activator as a prognostic factor in bladder cancer. Int J Cancer 1992;50:871-3.
169. 169 Nekarda H, Siewert J, Schmitt M, et al. Tumour-associated proteolytic factors u-PA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994;343:117.
170. 170 Ganesh S, Sier CFM, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-71.
171. 171 Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type-1 on prognosis in cervical cancer of the uterus. Gynecol Oncol 1994;54:6539-48.
172. 172 Kuhn W, Pache L, Schmalfeldt B, et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical and platinum-based chemotherapy. Gynecol Oncol 1994;55:401-9.
173. 173 Hofmann R, Lehmer A, Buresch M, et al. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78:487-92.
174. 174 Duffy MJ, Reilly D, McDermott E, et al. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994;74: 2276-80.
175. 175 Janicke F, Schmitt M, Pache L, et al. Urokinase plasminogen activator (u-PA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;53:135-44.
176. 176 Oka T, Ishida T, Nishino T, et al. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumours of pulmonary adenocarcinoma. Cancer Res 1991;51:3522-3.
177. 177 Pedersen H, Grondahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-3.
178. 178 Nagayama M, Sato A, Hayakawa H, et al. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumour dissemination. Cancer 1994;73: 1398-405.
179. 179 Ganesh S, Sier CFM, Heerding MH, et al. Urokinase receptor and colorectal cancer survival. Lancet 1994;344: 401-2.
180. 180 Duggan C, Maguire T, McDermott E, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995;61:597-600.
181. 181 Foekens JA, Schmitt M, van Putten WLJ, et al. Plasminogen activator inhibitor-1 and prognosis in breast cancer. J Clin Oncol 1994;12:1648-58.
182. 182 Pedersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor and type-1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
183. 183 Duggan C, Kennedy S, Kramer MD, et al. Plasmingen activator inhibitor type 2 in breast cancer. Br J Cancer 1997;76:622-7.
184. 184 Bouchet C, Spyratos F, Martin PM, et al. Prognostic value of urokinase plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398-405.
185. 185 Takeuchi Y, Nakao A, Harada A, et al. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastrol 1993;88:1928-33.
186. 186 Allam HS, Arand G, Lippman ME, et al. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Ins: 1993;85:1758-64.
187. 187 Fong KM, Kida Y, Zimmerman PV, et al. TIMP-1 and adverse prognosis in non-smail cell lung cancer. Clin Cancer Res 1996;2:1369-72.
188. 188 Karameris A, Panagou P, Tsilalis T, et al. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous cell lung carcinomas. Am J Respir Crit Care Med 1997;156:1930-6.
189. 189 Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996;56:1654-9.
190. 190 Ree AH, Florenes VA, Berg JP, et al. High levels of mRNA for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of metastases. Clin Cancer Res 1997;3:1623-8.
191. 191 Zeng ZS, Cohen AM, Zhang ZF, et al. Elevated tissue inhibitor of metalloproteinase-1 (TIMP-1) RNA jn colorectal cancer stroma correlates with lymph node and distant metastasis. Clin Cancer Res 1995;1:899-906.
192. 192 Davies B, Waxman J, Harpret W, et al. Levels of matrix metalloproteinases in bladder cancer correlate with tumour grade and invasion. Cancer Res 1993;53:1-5.
193. 193 Brown PD, Giavazzi R. Matrix metalloproteinases inhibition: a review of anti-tumour activity. Ann Oncol 1995;6:967-74.
194. 194 Chirivi RG, Garofalo A, Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994;58:460-4.
195. 195 Eccles SA, Box GM, Court WJ, et al. Control of lymphatic and haematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996;54:4726-8.
196. 196 Taraboletti G, Gardfalo A, Belotti O, et al. Inhibition of angiogenesis and murine angioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-8.
197. 197 Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 1991;47: 230-5.
198. 198 Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996;32A:2528-33.
199. 199 Hurewitz AN, Zucker S, Mancuso P, et al. Human pleural effusions are rich in matrix metalloproteinases. Chest 1992; 102:1808-14.
200. 200 Wojtowicz-Praga SM, Dickson RM, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest NewDrugs 1997;15:61 75.
201. 201 Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
202. 202 An Z, Wang X, Willmott N, et al. An orally-active synthetic MMP inhibitor CT1746 reduces tumour spread and metastasis converting aggressive colonic cancer into a more indolent disease in a nude-mice model. Clin Exp Metastasis 1997;15:184-95.
203. 203 Anderson IC, Shipp MA, Docherty AJP, et al. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastases of murine Lewis lung carcinoma. Cancer Res 1996;56:715-20.
204. 204 O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of primary tumours in mice. Nature Med 1996;2:689-92.
205. 205 Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
206. 206 Weidner N, Folkman J, Pozza C, et al. Tumour angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
207. 207 Fontanini G, Vignati S, Bigini D, et al. Microvessel count predicts metastatic disease and overall survival in non-small-cell lung carcinomas. J Pathol 1995;177:57-63.
208. 208 Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumour invasion: from correlation and causality to the clinic. Cancer Biol 1996;7:147-54.